Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.

Ryoo I, Choi SH, Kim JH, Sohn CH, Kim SC, Shin HS, Yeom JA, Jung SC, Lee AL, Yun TJ, Park CK, Park SH.

PLoS One. 2013 Aug 19;8(8):e71704. doi: 10.1371/journal.pone.0071704. eCollection 2013.

2.

Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.

Ahn SS, Shin NY, Chang JH, Kim SH, Kim EH, Kim DW, Lee SK.

J Neurosurg. 2014 Aug;121(2):367-73. doi: 10.3171/2014.5.JNS132279. Epub 2014 Jun 20.

PMID:
24949678
3.

A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.

Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, Sharma MC, Sharma BS, Mahapatra AK, Suri A, Sarkar C.

J Clin Neurosci. 2011 Jan;18(1):66-70. doi: 10.1016/j.jocn.2010.04.050.

PMID:
20888234
4.

Cerebral blood volume analysis in glioblastomas using dynamic susceptibility contrast-enhanced perfusion MRI: a comparison of manual and semiautomatic segmentation methods.

Jung SC, Choi SH, Yeom JA, Kim JH, Ryoo I, Kim SC, Shin H, Lee AL, Yun TJ, Park CK, Sohn CH, Park SH.

PLoS One. 2013 Aug 8;8(8):e69323. doi: 10.1371/journal.pone.0069323. eCollection 2013.

5.

Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.

Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D'Incerti L, Filippini G, Broggi G, Boiardi A, Finocchiaro G.

Clin Cancer Res. 2007 May 1;13(9):2606-13.

6.

Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.

Camara-Quintana JQ, Nitta RT, Li G.

Neurosurg Clin N Am. 2012 Apr;23(2):237-46, viii. doi: 10.1016/j.nec.2012.01.011. Epub 2012 Feb 22. Review.

PMID:
22440867
7.

Tumor blood flow from arterial spin labeling perfusion MRI: a key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas.

Yoo RE, Choi SH, Cho HR, Kim TM, Lee SH, Park CK, Park SH, Kim IH, Yun TJ, Kim JH, Sohn CH, Han MH, Chang KH.

J Magn Reson Imaging. 2013 Oct;38(4):852-60. doi: 10.1002/jmri.24026. Epub 2013 Feb 6.

PMID:
23390061
8.

Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.

Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, Lee JI, Park K, Kim JH, Nam DH.

AJNR Am J Neuroradiol. 2011 Feb;32(2):382-7. doi: 10.3174/ajnr.A2286. Epub 2011 Jan 20.

9.

Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.

Provenzale JM, York G, Moya MG, Parks L, Choma M, Kealey S, Cole P, Serajuddin H.

AJR Am J Roentgenol. 2006 Oct;187(4):1036-42.

PMID:
16985154
10.

Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.

Sunwoo L, Choi SH, Park CK, Kim JW, Yi KS, Lee WJ, Yoon TJ, Song SW, Kim JE, Kim JY, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Chang KH.

J Magn Reson Imaging. 2013 Feb;37(2):351-8. doi: 10.1002/jmri.23838. Epub 2012 Sep 28.

PMID:
23023975
11.

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.

Romano A, Calabria LF, Tavanti F, Minniti G, Rossi-Espagnet MC, Coppola V, Pugliese S, Guida D, Francione G, Colonnese C, Fantozzi LM, Bozzao A.

Eur Radiol. 2013 Feb;23(2):513-20. doi: 10.1007/s00330-012-2601-4. Epub 2012 Aug 10.

PMID:
22875158
12.

Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading.

Server A, Graff BA, Orheim TE, Schellhorn T, Josefsen R, Gadmar ØB, Nakstad PH.

Neuroradiology. 2011 Jun;53(6):435-47. doi: 10.1007/s00234-010-0770-x. Epub 2010 Sep 21.

PMID:
20857284
13.

Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.

Gupta A, Young RJ, Shah AD, Schweitzer AD, Graber JJ, Shi W, Zhang Z, Huse J, Omuro AM.

Clin Neuroradiol. 2015 Jun;25(2):143-50. doi: 10.1007/s00062-014-0289-3. Epub 2014 Jan 29.

14.
15.

O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.

Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P, Sarkar C.

Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Review.

PMID:
21107199
16.
17.

Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.

Ramakrishnan V, Kushwaha D, Koay DC, Reddy H, Mao Y, Zhou L, Ng K, Zinn P, Carter B, Chen CC.

Cancer Biomark. 2011-2012;10(3-4):185-93. doi: 10.3233/CBM-2012-0245.

PMID:
22674304
18.

Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.

JAMA. 2009 Jul 15;302(3):276-89. doi: 10.1001/jama.2009.1022.

19.

Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study.

Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H.

Neuroepidemiology. 2009;32(1):21-9. doi: 10.1159/000170088. Epub 2008 Nov 8.

PMID:
18997474
20.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R.

Clin Cancer Res. 2004 Mar 15;10(6):1871-4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk